Clinical Trials Browser

Phase 1/2 × dupilumab × 90 days × Clear all

NCT07277322 2026-03-02

Neoadjuvant Dupilumab and Toripalimab in MSS CRC Subjects With Resectable Liver Metastases

Phase 1/2 Not yet recruiting

Gastrointestinal

Colorectal Neoplasms